Latest News of TEVA
Teva Pharmaceutical Industries Ltd (TEVA) Q3 2024 Earnings Call Highlights: Strong Revenue ...
By Yahoo! Finance |
1 week ago
Teva can benefit from US-made generics push and expects positive safety label for olanzapine LAI. Strong 2025 outlook for US generics and UZEDY patients from oral medications. TAPI divestment on track...
Corteva reports larger-than-expected loss on low demand and pricing
By Yahoo! Finance |
1 week ago
Corteva, a U.S. agrichemicals company, reported a larger loss than expected due to reduced sales and prices. The company cut its full-year sales outlook due to decreased demand for crop chemicals, imp...
Teva Pharmaceutical Industries (TEVA) Q3 2024 Earnings Call Transcript
By Yahoo! Finance |
1 week ago
Teva Pharmaceuticals reported strong performance in Q3 2024. The company is focused on growth strategies with innovative products like AUSTEDO, AJOVY, and UZEDY. Progress in the pipeline includes Phas...
-
Teva's Explosive Q3 Results: Pivot to Growth Strategy Shocks Investors with Record Revenue Surge
By Yahoo! Finance | 1 week agoTeva Pharmaceuticals impresses with a 13% revenue growth in Q3 2024, reaching $4.3 billion. Boosted by U.S. generics and successful therapies like Austedo and Uzedy, Teva's strategic shift is proving ...
-
Teva Flashes A Buy Signal On Upbeat Third-Quarter Report
By Investor's Business Daily | 1 week agoTeva's stock surged after reporting Q3 earnings of 69 cents per share on $4.33 billion in sales, beating analyst expectations. Teva raised its full-year outlook to $16.1-$16.5 billion in sales and $2....
-
Teva Pharmaceutical Industries (TEVA) Reports Q3 Earnings: What Key Metrics Have to Say
By Yahoo! Finance | 1 week agoTeva Pharmaceutical Industries reported $4.33 billion in revenue for the quarter ended September 2024, up 12.5% YoY, with an EPS of $0.69. The company exceeded revenue and EPS estimates, showcasing gr...
-
Teva's long-lasting schizophrenia injectable shines in Phase III
By Yahoo! Finance | 2 weeks agoTeva Pharmaceuticals' TEV-479 (olanzapine) showed significant improvements in schizophrenia symptoms and quality of life in a Phase III trial. The study revealed positive results across different dose...
-
EC fines Teva $502m over multiple sclerosis treatment Copaxone practices
By Yahoo! Finance | 2 weeks agoThe European Commission fined Teva Pharmaceuticals Industries €462.6m for anti-competitive practices related to multiple sclerosis treatment Copaxone. Teva extended patent protection, disseminated m...
-
EU Commission fines Teva $500 million for trying to stop rival's multiple sclerosis drug
By Yahoo! Finance | 2 weeks agoThe European Commission fined Teva over $500 million for manipulating patents and discrediting a rival's drug. Teva's actions hindered competition and cost countries significant savings. Teva was also...
-
Teva Returns to Growth as Hoka and Ugg Continue to Drive Q2 Sales at Deckers
By Yahoo! Finance | 3 weeks agoAdidas raises full-year revenue outlook after strong Q3, while Deckers reports a 20.1% increase in net sales for Q2. Brands like Hoka and Ugg lead the growth, with Deckers raising its guidance for fis...
-
Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory
By Yahoo! Finance | 3 weeks agoTeva Pharmaceutical Industries has faced challenges but shows potential for growth. With a focus on expanding branded products and innovative treatments like Austedo, Teva aims to capture new revenue ...
-
Saskatchewan election 2024: Estevan-Big Muddy | Globalnews.ca
By Global News | 1 month agoEstevan-Big Muddy is a new riding in southern Saskatchewan, with Lori Carr as the previous MLA. The upcoming 2024 election will determine the representative, with results available on election night....
-
Teva Pays $450M To Resolve Alleged Kickback, Price-Fixing Schemes
By Yahoo! Finance | 1 month agoTeva Pharmaceuticals has settled a $450 million case with the U.S. government for violating the Anti-Kickback Statute and False Claims Act. The settlement involves two kickback schemes and includes $2...
-
Teva pays $450 million to settle kickback scheme charges
By Yahoo! Finance | 1 month agoTeva Pharmaceuticals has agreed to pay $450 million to resolve claims of violating the Anti-Kickback Statute. The company engaged in schemes to manipulate drug prices, including paying copays for its ...
-
Teva agrees to pay $450m to resolve kickback allegations, US Justice Dept says
By Yahoo! Finance | 1 month agoTeva, a drugmaker, will pay $450 million to settle claims of violating anti-kickback laws and the False Claims Act. The Justice Department emphasized the harm caused by kickbacks in healthcare decisio...